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Abstract
Background: Postulating that serotonin (5-HT), released from smoking-activated platelets could be involved in smoking-
induced vascular modifications, we studied its catabolism in a series of 115 men distributed as current smokers (S), never
smokers (NS) and former smokers (FS) who had stopped smoking for a mean of 13 years.
Methodology/Principal Findings: 5-HT, monoamine oxidase (MAO-B) activities and amounts were measured in platelets,
and 5-hydroxyindolacetic acid (5-HIAA)—the 5-HT/MAO catabolite—in plasma samples. Both platelet 5-HT and plasma 5-
HIAA levels were correlated with the 10-year cardiovascular Framingham relative risk (P,0.01), but these correlations
became non-significant after adjustment for smoking status, underlining that the determining risk factor among those
taken into account in the Framingham risk calculation was smoking. Surprisingly, the platelet 5-HT content was similar in S
and NS but lower in FS with a parallel higher plasma level of 5-HIAA in FS. This was unforeseen since MAO-B activity was
inhibited during smoking (P,0.00001). It was, however, consistent with a higher enzyme protein concentration found in S
and FS than in NS (P,0.001). It thus appears that MAO inhibition during smoking was compensated by a higher synthesis.
To investigate the persistent increase in MAO-B protein concentration, a study of the methylation of its gene promoter was
undertaken in a small supplementary cohort of similar subjects. We found that the methylation frequency of the MAOB
gene promoter was markedly lower (P,0.0001) for S and FS vs. NS due to cigarette smoke-induced increase of nucleic acid
demethylase activity.
Conclusions/Significance: This is one of the first reports that smoking induces an epigenetic modification. A better
understanding of the epigenome may help to further elucidate the physiopathology and the development of new
therapeutic approaches to tobacco addiction. The results could have a larger impact than cardiovascular damage,
considering that MAO-dependent 5-HT catabolism is also involved in addiction, predisposition to cancer, behaviour and
mental health.
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Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is a potent biogenic
amine, first described as a vasoconstrictor compound contained in
the serum and later identified as a neurotransmitter [1]. Once
synthesized in the gastrointestinal tract, peripheral 5-HT is actively
taken up by platelets which store the amine within their dense
granules. As a result, 5-HT is widely distributed in the body
through the blood flow. 5-HT storage within platelets is held
against such a high concentration gradient that it protects the
organism from 5-HT-induced vascular tone abrupt modifications,
maintains the 5-HT plasma level in the low nM range and
prevents the amine of being degraded. Under normal physiolog-
ical conditions, however, platelet granule-stored 5-HT can be
either released into the blood flow through the open canalicular
system or exposed to the platelet mitochondrial monoamine
oxidase (MAO). In the latter case, it is degraded principally to 5-
hydroxyindole acetic acid (5-HIAA) which also passes through the
open canalicular system into the blood.
Degradation of bioamines mainly occurs through monoamine
oxidases (MAOs). There are two MAO isoforms: MAO-A
preferentially degrades endogenous bioamines such as 5-HT and
norepinephrine, and MAO-B preferentially degrades exogenous
bioamines such as phenylethylamine and benzylamine [2]. These
specificities are relative, however. Human platelets and lympho-
cytes contain only the MAO-B isoform. Human MAOA and
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7959MAOB genes are both located on the short arm of the X
chromosome (Xp.11.4–11.3, [3]). The two genes are arranged in a
tail-to-tail orientation, and both span at least 60 kb, consist of 15
exons, and exhibit an identical exon-intron organization [4].
High 5-HT levels have been proposed to be predictive of
coronary artery diseases, especially in young people [5]. In
addition, inhibitors of 5-HT uptake, the so-called specific
serotonin reuptake inhibitors (SSRIs) used in the treatment of
depression and other psychiatric disorders [6], reduce the
cardiovascular complications by inhibiting platelet activation and
aggregation [7]. We therefore decided to measure the platelet 5-
HT levels and to study its catabolism in a series of untreated
healthy men at low risk for cardiovascular disease.
Unexpectedly, the greatest modifications in 5-HT catabolism
were found in former smokers (FS) rather than in current smokers
(S) as compared to subjects who had never smoked (NS). We found
that smoking induced an epigenetic regulation of MAOB, i.e. a
reduction of its gene promoter methylation, resulting in high




The studied population was 115 men aged from 35 to 56 years
free from stroke, transient ischemia, coronary heart disease,
congestive heart failure and intermittent claudication. The usual
biological variables were measured on an LX20 automate
(Beckman-Coulter). Ten-year risk of coronary event was calculated
by the Framingham equations on the basis of age, gender, systolic
BP, total to HDL cholesterol ratio, and smoking [8]. Relative risk
(RR) was calculated as the actual divided by the ideal
(normotensive, normocholesterolemic, non smoker subject for
each age category) 10-year coronary risk. All clinical investigations
were conducted according to the Declaration of Helsinki principles
and written informed consents were obtained from all subjects
prior to inclusion in the study. The local Research Ethics Board
approved the study protocols (Comite ´ de Protection des Personnes
Assistance Publique –Ho ˆpitaux de Paris 06–223).
During the study it was decided to analyzed the methylation
patterns of the MAOB core promoter. A supplementary cohort of
13 subjects were therefore recruited with consent for a genetic
study.
Smoking Status and Classification
Smoking status, duration of smoking, number of years since
quitting and lifelong smoking dose were carefully assessed by
questioning the subjects. Subjects were classified into three groups
on the basis of their smoking status: (i) never smokers (NS); (ii)
current smokers (S) – those who currently smoked daily or had
smoked for the previous year, regardless of the amount smoked;
and (iii) former smokers (FS) - those who had smoked, but had quit
one year ago or more. Occasional smokers who had not quit for at
least one year were not included in the study.
Ultrasound Investigation
Ultrasonography was performed by experienced sonographer
physicians using a 7.5 MHz probe for the extracranial carotid and
femoral arteries and a 3-MHz probe for the abdominal aorta, as
previously described [9]. Data were classified into two categories:
absence or presence of any atherosclerotic arterial plaque(s). The
intima media thickness (IMT) was measured on the common
carotid artery on both sides in the far wall of at least 1 cm of
longitudinal length, and calculated as previously described [10].
Platelet, Peripheral Blood Mononuclear Cells (PBMC) and
Plasma Preparation, Platelet Aggregation
Blood was drawn in 3.8% sodium citrate-anticoagulated tubes.
Whole blood aggregometry was measured using 500 mL aliquots of
blood diluted 1:1 (v/v) in saline under constant stirring by the
impedance technique, after addition of 2 mg/mL of collagen.
Platelet rich plasma (PRP) was obtained by 10 min centrifugation
at 100 g (20uC) and platelet poor plasma (PPP) by 10 min
centrifugation at 20uC at 1500 g. Both were stored at 280uC until
analysis (within 2 weeks). PBMC were obtained from each subject
of the supplementary cohort using the standard Ficoll-Hypaque
procedure.
5-HT and 5-HIAA Measurements
5-HT and its deaminated metabolite 5-HIAA were measured
using HPLC, as described by Kema et al. [11] in PRP and PPP
samples, respectively.
MAO Activities and Protein Concentrations
MAO (EC.1.4.3.4.) enzymatic activity was determined as
previously reported [12] on human PRP or PBMC samples by a
radioenzymatic assay using [
14C]-b-phenylethylamine (2.07 GBq/
mmol, Amersham GE Healthcare, Saclay, F, final concentration
20 mM) as substrate. The MAO activity measured by this method
is fully accounted for by MAO-B. Platelet MAO-B protein
concentration was assessed for each subject by measuring the
binding of [
3H]-Ro 19-6327 [N-(2-aminoethyl)-5-chloropicolina-
mide HCl, lazabemide] (0.96 TBq/mmol, Amersham GE
Healthcare), a reversible inhibitor of MAO-B, to human platelet
membranes, as described by Cesura et al. [13] for [
3H]Ro 16-6491.
The same protocol was applied to human PBMC, mouse platelets
and mouse lung tissue. MAO-A activities and concentrations in
mouse lungs were determined exactly as for MAO-B except that
[
14C]-5-HT creatinine sulfate (1.96 GBq/mmol, Amersham GE
Healthcare, Saclay, F,) and [
3H]-Ro 41-1049 (0.31 TBq/mmol,
Amersham GE Healthcare) were used as substrate and radioligand
respectively. Platelet MAO-B protein concentration was also
assessed by western blot: a total of 10 mg proteins were resolved by
4–12% Bis-Tris NuPAGE; separated proteins were electrotrans-
ferred to polyvinylidene difluoride membrane (Novex, San Diego,
CA) and incubated with specific antibody to MAO-B (C-17, Santa
Cruz Biotechnology Inc., Santa Cruz, CA).
Sodium Bisulfite Genomic Sequencing of the MAOB
Promoter
Genomic DNA was obtained from PBMC using standard
procedures. Bisulfite treatments were performed as described [14]
with minor modifications. A fragment of the genomic DNA of the
MAOB promoter (Genbank M89637 59flanking sequence 255 to
2752 bp) was amplified using the following primers: 59-
GCCTTCCTGACTTAATCAC-39 (forward -752) and 59-
CCTCGATCCCAGTCCTGCC-39 (reverse -55). PCR amplifi-
cation was performed with 5 mL of bisulfite-modified DNA with
an annealing temperature of 56uC. PCR products were cloned
into pCR II and sequenced.
DNA Methyltransferase and Nucleic Acid Demethylase
Activities of Mouse Lung
Male A/J mice, aged 6 to 8 weeks (Charles River, Orle ´ans, F)
were exposed to filtered air or mainstream cigarette smoke (10
mice in each group) using the exposure regimen developed by
Witschi et al. [15] at a concentration of 250 mg/m
3 of total
suspended particulates for 5.5 hours/day, 5 days/week for 5
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in accordance with institutional guidelines (INSERM, Saint Louis
Hospital) and approved by the French Animal Care Committee.
Nuclear extracts were prepared from lungs according to the
protocol of Dignam et al. [16]. DNA methyltransferase activity was
determined as described previously [17]. The nucleic acid
demethylase activity of the mouse lung nuclear extracts was
assayed as their ability to demethylate 3-methylcytosine in [
14C]-
methylated poly(dC). Demethylation was assayed according to
[18], the only change being the replacement of the mouse reelin
promoter by the mouse MAOB promoter.
Statistical Analysis
It was carried out with the use of JMP (SAS) and Excel
(Microsoft) softwares. For all tests, statistical significance was set at
P,0.02 (a, two-sided type 1 error of ,2%).
Overall Study Sample
Continuous parameters are expressed as means 6 SD.
Normality of the distribution was analyzed by the Shapiro-Wilk
W test. Normally-distributed variables were compared between
smoking status groups by ANOVA, pairwise comparisons being
performed by using the Student’s t-test. Non normally-distributed
variables were compared between smoking status groups by non
parametric (Wilcoxon and Kruskal-Wallis) tests. Qualitative
parameters are expressed as percent of subjects and compared
between smoking status groups by the chi-square test. Linear
regressions were used to analyze the relationships between
continuous parameters, after logarithmic transformation in the
case of non normal distribution.
In subjects recruited for the genetic study and in mice studies
enzyme activities and concentrations were compared between
groups by Fisher’s exact test.
Results
Characteristics of Subjects
Subjects referred to the ‘‘Centre de Me ´decine Pre ´ventive
Cardio-Vasculaire’’ between January 2003 and January 2007 for
cardiovascular risk assessment were included in the study (i) if they
had one or more mild cardiovascular risk factors among
hypertension (defined as systolic blood pressure (BP) between
140 and 160 mm Hg and/or diastolic BP between 90 and 95 mm
Hg), hypercholesterolemia (defined as total cholesterol after
subjects had fasted for 14 hours between 5.2 and 7.2 mmol/L)
and smoking; (ii) if they were free from diabetes (fasting blood
glucose level ,7 mmol/L), from obesity (body mass index
,30 kg/m
2) and from anti-hypertensive, lipid-lowering, anti-
diabetic and platelet anti-aggregant therapies and SSRI drugs.
The clinical profile of the studied population in relation to the
smoking status is shown in Tables 1 and 2. The smoking group was
typical [19], i.e. with more femoral plaques and higher number of
atherosclerotic sites (Table 2). Smoking duration was higher in S
than in FS group (P,0.02) but lifelong cumulative consumption,
as reflected by pack.years, was not different between the two
groups (Table 2).
Platelet Aggregation, Platelet 5-HT and Plasma 5-HIAA
Most studies dealing with smoking have compared S and NS,
thus initially, in this study, only two groups were compared, i.e.
current smokers [S] and current non-smokers who had not smoked
for at least one year on the day of blood sampling (thus including
never smokers [NS] and former smokers [FS]). In response to
2 mg/mL collagen, platelet aggregation amplitude in whole blood
was similar in the two groups (1665 vs. 1664 ohms), whereas the
aggregation velocity (ohms.min
21) was significantly lower
(P,0.01) in S (7.960.5) than in NS+FS (10.360.6). The platelet
5-HT content was almost identical in the two groups (S and
NS+FS), as was plasma 5-HIAA, (Fig. 1A, B).
This surprising lack of differences between current smokers (S)
and current non-smokers (NS + FS) prompted a further analyze of
the NS + FS group in order to differentiate those who had never
smoked (NS) from those who had smoked but had quit one year
ago or more, i.e. former smokers (FS). The less rapid aggregation of
smokers’ platelets was confirmed (velocity 7.960.5 ohms min
21
for S vs. 10.160.6 and 11.061.2 for FS and NS respectively,
P,0.01). The distinction between NS and FS also indicated that
platelet aggregation velocity returned to normal after quitting
smoking.
The discrimination of FS in the non-smoking group demon-
strated that FS had a significantly reduced platelet amount of 5-
HT as compared to NS and S (Fig. 1A). It is therefore possible that
5-HT was released from the storage granules of FS platelets and,
once released, was degraded to 5-HIAA. Indeed, the 5-HIAA
amounts measured in FS plasmas were significantly higher than in
NS and S (Fig. 1B).
Platelet Monoamine Oxidase
The fact that platelet 5-HT was more degraded into 5-HIAA
suggested that the enzyme responsible for this degradation, MAO,
was either more active or more abundant in FS. MAO activity and
MAO protein concentration were therefore measured in platelets
since this is the most easily accessible source of MAO. As
previously reported [2,12,20], MAO-B (the only isoenzyme
present in human platelets) activity was significantly weaker
(Fig. 1C) in current smokers (S) than in current non-smokers (NS +
FS). But when discriminating FS in the current non-smoking
group, MAO-B activity was found at a similar level in S and NS,
whereas it was significantly greater in FS (Fig. 1C).
This higher platelet MAO activity found in FS was explained by
a higher MAO-B protein concentration than in NS as assessed by
both binding and western blot (Fig. 1D). Unexpectedly however,
the platelet MAO protein concentration was also higher in S
(Fig. 1D). Calculation, for each subject, of the specific activity of
the enzyme, i.e. the ratio of MAO-B activity to its protein
concentration, showed that the lowest mean MAO-B catalytic
activity was that of S platelets where one enzyme molecule
hydrolyzed 9,000 molecules of substrate per hour as compared to
NS (13,000) and FS (11,000). Moreover, platelet 5-HT and plasma
5-HIAA levels were highly correlated (P,0.001, not shown) with
both platelet MAO activities and protein concentration.
To our knowledge, this is the first report showing distinct
measures of platelet MAO activities and protein concentrations in
smokers. The present results reassert that MAO-B activity is
inhibited by smoking and reveal for the first time that (i) platelet
MAO-B protein concentration increased during smoking and (ii)
this increase lasted long after quitting smoking (13 yrs average in
our FS group, Table 2).
5-HT Catabolism and Cardiovascular Risk
In order to evaluate possible relationship(s) between the 5-HT
catabolism and the cardiovascular risk, correlation(s) were sought
between the studied markers of 5-HT catabolism and the
cardiovascular risk reference, the Framingham risk score. Platelet
5-HT and plasma 5-HIAA levels did not correlate with smoking
duration but were both significantly (P,0.02) correlated with the
Framingham risk score, positively for platelet 5-HT and negatively
for plasma 5-HIAA (Fig. 2A). However, these correlations became
Serotonin and Smoking Status
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SMOKING STATUS
Parameter Non smokers (NS) Smokers (S) Former Smokers (FS) P Value
n=34 (29.6%) n=44 (38.2%) n=37 (32.2%)
Age, yrs 48684 6 694 9 67 0.25
Body mass index, kg/m
2 26642 6 632 7 63 0.30
Blood pressure, mmHg
systolic 127615 126612 129615 0.71
diastolic 81610 77688 0 610 0.20
Hypertensive patients, n (%) 8 (23.5) 7 (16.0) 8 (23.5) 0.23
Lipid status
total cholesterol, mmol/L 5.560.7 6615 . 7 61.1 0.10
HDL cholesterol, mmol/L 1.160.3 1.160.3 1.260.3 0.43
LDL cholesterol, mmol/L 3.660.9 4.160.9 3.761 0.03
Hypercholesterolemic patients, n (%) 24 (70.6) 33 (75.0) 26 (76.5) 0.87
triglycerides, mmol/L 1.260.7 1.761.1 1.560.9 0.08
lipoprotein A, g/L 0.360.3 0.460.4 0.360.3 0.08
Glycemia, mmol/L 5.260.5 5.260.6 5.360.5 0.76
Creatininemia, mmol/L 87611 81612 85610 0.52
Folates, ng/ml 6.5636 . 3 635 . 6 62 0.41
Homocystein, mmol/L 9621 0 631 0 63 0.24
Data are means 6 SD or number and percent of subjects, n (%). There was no significant difference between NS, S, and FS and the frequencies of hypertension and
hypercholesterolemia were similar in all three groups.
doi:10.1371/journal.pone.0007959.t001
Table 2. Smoking, inflammation, blood parameters and atheromatous profile of 115 patients according to their smoking status.
SMOKING STATUS
Parameter Non smokers (NS) Smokers (S) Former Smokers (FS) P Value
n=34 (29.6%) n=44 (38.2%) n=37 (32.2%)
Smoking parameters (S vs FS)
cigarettes per day 0 19630 -
yr of smoking 0 23611 8 62 0.02
yr since quitting 0 0 1368-
packs.yrs 0 23617 18611 0.15
Inflammation and blood profile (overall)
C reactive protein, mg/L 1.361.2 2622 63 0.10
fibrinogen, g/L 2.860,5 3.160.5 360.4 0.06
hematocrit, % 42624 4 634 3 62 0.06
hemoglobin, g/100 mL 14.460.7 14.860.8 1561 0.10
leukocytes, G/L 5617 626 61 0.0001
platelets, G/L 224641 224655 242646 0.23
Atheromatous profile (overall)
presence of plaque at any site, n (%) 14 (41) 31 (70.5) 22 (59.5) 0.05
presence of carotid plaque, n (%) 9 (26.5) 19 (43) 10 (27) 0.21
presence of femoral plaque, n (%) 9 (26.5) 29 (66) 16 (43) 0.002
presence of aortic plaque, n (%) 7 (21) 16 (36) 8 (22) 0.21
Intima media thickness, mm 0.5660.07 0.6060.10 0.6060.10 0.55
Data are means 6 SD, or number and percent of subjects n (%).
doi:10.1371/journal.pone.0007959.t002
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that the determining risk factor among those taken into account in
the Framingham risk calculation was smoking. In contrast, the
platelet MAO protein concentration correlated (P,0.02) with the
duration of smoking (Fig. 2B), but not with the Framingham risk
score, indicating that the MAO protein concentration is linked to
the life-long smoking rather than to the multifactorial cardiovas-
cular risk. Finally, the MAO activity did not correlate with any
studied marker other than platelet 5-HT or plasma 5-HIAA,
except with the number of cigarette per day for S + FS (P,0.02,
not shown) as previously observed [21].
Methylation of the MAO Gene Promoter
The platelet MAO-B protein concentration remaining elevated
several years after quitting smoking suggested a smoking-induced
gene modification. A detailed analysis reported that the human
MAOB core promoter contains 22 CpG sites that can be
methylated, with methylation reducing the transcription of MAOB
[22]. Such a genetic approach had not been considered when
subjects were recruited. The methylation patterns of the MAOB
core promoter were therefore analyzed in a supplementary cohort
of subjects (5 S, 4 FS, 4 NS) with consent for a genetic study and
clinically identical to the initial cohort (Table 3). This similarity
also concerns metabolites related to methylation efficiency (i.e.
folates and homocystein, P.0.05 between Tables 1 and 3 for these
parameters). As for the previous population, the platelet MAO-B
protein concentration (pmoles.mg protein
21) was the lowest in NS
patients’ platelets (1.160.1 vs 5.960.9 and 6.061.1 in S and FS,
P,0.02), whereas the MAO-B activity (nmoles.mg protein
21.h
21)
was the highest in FS platelets (57615 vs 2163 and 2562 in S and
NS, respectively; P,0.02).
DNA analysis was performed on PBMC of S, FS and NS of
subjects of the supplementary cohort, which exhibited MAO
profiles (Fig. 3, insert) similar to platelets. These confirmed that
platelet MAO protein concentration was increased during
smoking. The methylation frequency was notably higher for NS,
both at each of the 22 sites (Fig. 3A, left) or as the mean of the 22
sites (Fig. 3A, right). The extent of methylation of each CpG in
each sample is given in Table S1. According to the repressing
effect of DNA methylation upon general gene transcription [23]
and upon specific transcription of the human MAOB [22], the
individual methylation frequencies were negatively correlated with
the platelet MAO-B protein concentrations of the 13 studied
patients (Fig. 3B). These findings offer an explanation for the high
MAO-B protein concentration remaining long after quitting
smoking.
In order to verify that tobacco smoke is responsible for this
methylation change, DNA methyltransferase and nucleic acid
demethylase activities were measured in lung nuclear extracts of
mice exposed to cigarette smoke. These mice exhibited platelet
(MAO-B, Fig. 4 insert) and lung (MAO-B and MAO-A, Fig. 4A)
MAO profiles comparable to those found in human S patient’s
platelets, i.e. higher protein concentration and lower activity in
‘‘smoking’’ mice (Sm) than in ‘‘non-smoking’’ mice (NSm). The
PBMC methylation pattern of the MAOB core promoter was lower
in Sm (27.663.4 vs. 48.762.5%, P,0.05). It is noteworthy that
platelet 5-HT levels were increased after smoking (26.561.5 vs.
20.261.2 nmoles/mg protein, P,0.02) The lung DNA methyl-
transferase activity was not significantly different (Fig. 4B), whereas
the nucleic acid demethylase activity was significantly higher in
Sm (Fig. 4C). Moreover, the in vitro nucleic acid demethylase
activity of mouse lung nuclear extracts was increased by harman
Figure 1. Platelet 5-HT catabolism according to smoking status. PRP 5-HT (1A) and PPP 5-HIAA (1B) were measured by HPLC in samples of 34
NS, 44 S and 37 FS. Results are means as nmoles 5-HT/10
9 platelets and as nM 5-HIAA. Bars represent standard deviations. Significance: *P,0.001.
None of the patients studied had a storage pool disease (,0.5 nmoles/10
9 platelets). Platelet MAO-B activities (1C) were determined on PRP samples
of 34 NS, 44 S and 37 FS by radioenzymology. Results are given as nmoles of substrate per mg protein and per hour. Platelet MAO-B protein
concentrations (1D) were assessed both by Western blot and by measuring the binding of a reversible inhibitor of MAO-B to platelet membranes of
34 NS, 44 S and 37 FS and are expressed as pmoles of MAO-B per mg platelet protein. Results are mean values and bars represent standard
deviations. Significance: *P,0.001; {P,0.00001.
doi:10.1371/journal.pone.0007959.g001
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NS 45 5.4 1.1 3.1 1.4 0.3 5.4 91 7.6 9.1
NS 46 5.9 1.2 3.3 1.7 0.3 5.7 82 7.4 8.5
NS 43 4.8 1.2 3.5 1.3 0.4 5.2 89 7.5 10.4
NS 47 5.1 1.4 3.6 1.6 0.5 5.4 75 6.9 9.8
FS 50 (17) 9 5.5 1.4 4.9 1.4 0.3 5.1 91 8.9 9.2
FS 46 (16) 10 5.4 1.6 4.1 1.3 0.5 5.0 80 6.9 10.1
FS 47 (13) 13 5.3 1.3 4.4 1.3 0.5 6.3 81 8.1 11.0
FS 51 (12) 9 5.1 1.2 4.1 1.7 0.3 4.8 87 7.1 7.2
S 48 (19) 5.5 1.2 4.0 1.2 0.2 5.0 89 6.7 8.4
S 49 (17) 6.0 1.5 3.9 1.4 0.1 5.6 70 6.0 9.1
S 46 (15) 6.1 1.0 3.8 1.7 0.2 5.5 77 7.0 9.6
S 48 (16) 5.9 0.9 3.9 1.9 0.1 5.5 81 6.3 7.7
S 49 (14) 5.7 0.9 3.5 1.4 0.5 5.4 84 6.5 9.3
This new series was clinically identical to the initial cohort (Table 1).
doi:10.1371/journal.pone.0007959.t003
Figure 2. Serotonin catabolism, cardiovascular risk and smoking status. Correlations between (A) the Framingham Risk score and platelet 5-
HT contents (n=100, r=0.27, P,0.01) or plasma 5-HIAA levels (n=101, r=20.25, P,0.02) and between (B) MAO-B amount and smoking duration
(n=101, r=0.25, P,0.02).
doi:10.1371/journal.pone.0007959.g002
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smoke [24,25]. Demethylase activity was increased by 12.360.4
and 9.660.5% for harman and norharman (100 nM), respectively
(n=3).
Discussion
The present report is one of the very few to differentiate former
smokers (FS) from those who have never smoked in terms of
platelet 5-HT catabolism. 5-HT content was significantly reduced
in platelets of FS who had quitted smoking for a mean of 13 years.
This smoking-induced long-lasting effect was due to demethylation
of the MAOB gene promoter which resulted in a persistent high
protein concentration of platelet MAO-B. Moreover, results
obtained in two species (human and mice), with three cell types
(platelets, PBMC, lung cells) and concerning both MAO
isoenzymes, indicate that this smoking-induced MAO gene
deregulation could have a more general impact than vascular
modifications.
Platelets from smokers have been reported to show increased
aggregability [26] and to be more prone to spontaneous
aggregation [27]. Platelet aggregation was studied with platelet
rich plasma or isolated platelets. Under similar conditions, we
could not find any difference (not shown), the sensitivity of the
turbidimetric method possibly being too low. Platelet aggregation
has also often been measured after acute smoking of 1–3 cigarettes,
accounting for some discrepancies in the litterature. Here, we
measured platelet aggregation in whole blood, i.e. in the
physiological platelet environment which might differ from one
group to the other. Fitting with a trend for a higher fibrinogen
plasma level (Table 2) and thus a higher blood viscosity in S [28],
the collagen-induced aggregation velocity was significantly lower
for S than for NS and FS. This result emphasizes the importance
of studying platelet functions in whole blood.
Platelet activation has been reported for both acute and
chronic smokers with more activation markers exposed on
platelet surface [29,30]. The present results suggest that this
smoking-induced platelet activation may not be sufficient to
release the stored 5-HT from dense granules since similar 5-HT
content was found in platelets from S or NS. Only FS platelets
had lower levels of 5-HT, a finding consistent with the
deficiency of the vesicular monoamine transporter reported in
platelets of smokers [31] leading to a platelet dense granule 5-
HT storage defect. Accordingly, we found a higher 5-HIAA
level in FS plasma. The untransformed 5-HT released from
platelet into plasma is largely diluted, and plasma 5-HT
concentrations were not significantly different between the three
groups (not shown).
Figure 3. Analysis of the MAOB gene promoter methylation status. A Left: methylation frequencies at each CpG site within the human MAOB
gene core promoter. Values (%) are means for each group (4 NS, 5 S, and 4 FS). A Right: mean methylation frequency of the 22 CpG sites of the MAOB
gene promoter according to the smoking status (4 NS, 5 S, 4 FS) (*P,0.0001). B: correlation between the mean methylation frequencies of the MAOB
gene promoter 22 CpG sites and the platelet MAO amounts (n=13, r=0.70, P,0.001). Insert: PBMC MAO-B activity (nmoles.mg protein
21.h
21) and
protein concentrations (pmoles.mg protein
21) according to the smoking status of the subjects in the genetic study (4 NS, 5 S, 4 FS). Significance:
*P,0.001.
doi:10.1371/journal.pone.0007959.g003
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metabolites (sulfo- and nitro(so)-conjugates, not shown), the higher
level of 5-HIAA in FS plasma could result from either more active
or in higher quantity of platelet MAO-B. MAO-B activity has
been repeatedly reported to be lower in current smokers than in
non smokers [2,12,20,32]. Here, the distinct measurement of
MAO activities and of MAO protein concentrations shows that
the FS group accounts for the significantly higher platelet MAO-B
activity found in ‘‘current non-smokers’’. In addition, the platelet
MAO protein concentration was elevated in FS and also in S.
More MAO-B protein would be expected to result in higher
MAO-B activity in the two groups. Yet, this was only true for FS
but not for S. Calculation of the MAO-B catalytic activity, showed
that the lowest activity was found in S platelets, in agreement with
the low MAO-B activity typically found in current smokers
[2,12,20]. This is consistent with the fact that MAOs are oxygen-
dependent and carbon monoxide-inhibited enzymes [2]. This
inhibition of MAO-B catalytic activity during smoking is also in
agreement with PET-scan data obtained with brain [32] and
peripheral organs [33] of smokers, non-smokers and ex-smokers
using a radiotracer which binds irreversibly to MAO-B. On
average MAO-B is inhibited by over 40% in smokers vs. non-
smokers with no significant difference between brains of non- and
ex-smokers. Two reports assessing whether MAO inhibition
recovers after an overnight abstinence [34] or after 10–31 days
of smoking abstinence [21] concluded that (i) the enzyme is
irreversibly inhibited by compounds in cigarette smoke, and (ii)
after smoking cessation, MAO activity probably returns to normal
through de novo synthesis of the enzyme. The present study
supports these conclusions and proposes a mechanism regulating
MAO-B inhibition and slow recovery.
The present study shows that MAO activity was inhibited
during smoking and restored after quitting, whereas MAO protein
concentration was increased during smoking and remained high
for many years after quitting. The persistence of increased protein
concentrations of MAO-B was unexpected, even though some
haematological and inflammation characteristics remain modified
for several years after quitting smoking [19,35,36]. Smoking
Figure 4. Effect of cigarette smoke on DNA methyltransferase and nucleic acid demethylase activities in mice. Mice (10 per group)
were exposed (Sm) or not (NSm) to cigarette smoke and enzyme activities (A: MAO-A and MAO-B, B: DNA methyltransferase, and C: nucleic acid
demethylase) determined on lung extracts as described in the methods. Results are expressed as means 6 SD. Insert: platelet MAO activities
(nmoles.mg protein
21.h
21) and protein concentrations (pmoles.mg protein
21) according to the smoking status of mice. Significance: *P,0.001
doi:10.1371/journal.pone.0007959.g004
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new explanation. Three recent studies identify an association
between genetic variation on chromosome 15, in a region
containing the gene encoding the nicotinic acetylcholine receptor,
and risk of lung cancer [37–39]. A SNP is clearly linked to
smoking intensity [38]. The present study demonstrates how
epigenetics may also contribute to tobacco addiction and its long-
lasting effects after quitting. A higher methylation of MAOA has
been found associated with nicotine- and alcohol-dependence [40]
in women whereas a down-regulation of MAOA transcription has
been reported in several cancers including lung cancer [41]. Two
recent studies reported molecular alterations in spontaneous
sputum of cancer-free heavy smokers [42,43] and an association
of the offspring’s global DNA methylation with paternal global
DNA methylation, suggesting an association between smoking
behaviour and global DNA methylation [44].
Both S and FS exhibited reduced methylation of the MAOB
promoter, leading to a more active transcription of the gene and
hence a greater protein concentration of MAO-B. Moreover, ex
vivo animal experiments showed that tobacco smoke induced a
reduction in the MAOB promoter methylation. This is the first
report showing that smoking has a long-lasting effect in modifying
MAOB transcription. To date modified MAOB transcription had
only been shown during the differentiation of a human colon
adenocarcinoma cell line [22]. DNA methylation is a covalent
modification associated with long-term gene silencing with
potential links to tumorigenesis [23] and suicide [45]. Thus, the
epigenetic process found in the present report, which regulates
gene activity without altering the DNA code, might explain at least
some of the long-lasting effects and health problems generated by
smoking [19,35,36].
The nucleic acid demethylase activity, possibly due to
hyperactive poly(ADP-ribose) polymerases [46], is increased by
tobacco smoke (Fig. 4C) and generates aldehydes [24,47] (Fig. 5)
which are able to further cyclize bioamines to generate b-
carbolines, such as harman or norharman [2,24,25] from 5-HT.
In this way smoking might keep the MAO inhibited, contributing
to a sustained 5-HT neurotransmission, thus mimicking an
antidepressant effect (Fig. 5). In addition, b-carbolines, which
are inverse agonists of GABA-A receptors, can play a role in the
regulation of mood and anxiety states. Thus several data suggest
that tobacco smoke may have mood regulating properties [2,12].
Figure 5. Effect of cigarette smoke on serotonin (5-HT) catabolism. Cigarette smoke stimulates the nucleic acid demethylase activity (1.)
which generates aldehydes (HCHO) and demethylates the MAO promoter gene (2.). The demethylated MAO promoter gene leads to increased MAO
protein concentration (4). The aldehydes, by their action on methylene tetrahydrofolate reductase (3. MTHFR), lead to the formation of b-carbolines,
such as harman and norharman, from 5-HT. Harman and norharman are inhibitors of MAO activity (5.) and, being present in cigarette smoke*, keep
the sequence 1–5 switched on in smokers. The b-carbolines also act on GABA-A receptors, thus contributing to mood regulation. *The in vivo levels of
plasma harman (6.8 nM) and norharman (20.02 nM) reported in smokers [53] might also be high enough to stimulate nucleic acid demethylase
activity, as it is the case for platelet MAO-B inhibition [53].
doi:10.1371/journal.pone.0007959.g005
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animal models of psychiatric disorders [48]. More specifically,
keeping in mind that smoking is frequently abused by schizophre-
nia patients [49], nicotine (injected sub-cutaneously) was recently
found to decrease DNA methyltransferase 1 expression and
glutamic acid decarboxylase 67 promoter methylation in the
mouse frontal cortex [50].
5-HT is at the crossroads of several cardiovascular and
psychiatric diseases [51] and it has been suggested that MAO
may play an important role at this cross-section, as already shown
for alcoholic addiction [52] and predisposition to lung cancer
[38,41]. A better understanding of the MAO epigenome will help
in further elucidating the physiopathology and developing new
therapeutic approaches in tobacco addiction.
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